Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HU6 Tablet vs Capsule in Healthy Subjects
NCT06486558Phase 1Completed
- Sponsor
- Rivus Pharmaceuticals, Inc.
- Start
- Jul 2024
- Primary completion
- Nov 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HU6 in obesity, heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatohepatitis (MASH) (4 arms), sponsored by Rivus Pharmaceuticals, Inc. Primary endpoints: Area under the plasma concentration-time curve from time 0 to last quantifiable time point at 14 days and Maximum concentration at 14 days. Started Jul 2024; status: completed.
02
Drugs
HU6
03
Conditions
obesityheart failure with preserved ejection fraction (HFpEF)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06486558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06486558.